1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 21-29 of 29 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2011Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsTang, M.; Gonen, M.; Quintas-Cardama, A.; Cortes, J.; Kantarjian, H.; Field, C.; Hughes, T.; Branford, S.; Michor, F.
2012Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileParker, W.; Ho, M.; Scott, H.; Hughes, T.; Branford, S.
2012Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with NilotinibBranford, S.; Kim, D.; Soverini, S.; Haque, A.; Shou, Y.; Woodman, R.; Kantarjian, H.; Martinelli, G.; Radich, J.; Saglio, G.; Hochhaus, A.; Hughes, T.; Muller, M.
2007Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugsWhite, D.; Saunders, V.; Quinn, S.; Manley, P.; Hughes, T.
2003Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBranford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Hermann, R.; Seymour, J.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T.
2007Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemiaWhite, D.; Saunders, V.; Grigg, A.; Arthur, C.; Filshie, R.; Leahy, M.; Lynch, K.; To, L.; Hughes, T.
2011BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatmentStein, A.; Bottino, D.; Modur, V.; Branford, S.; Kaeda, J.; Goldman, J.; Hughes, T.; Radich, J.; Hochhaus, A.
2008Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsHiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
2017Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cellsWang, J.; Lu, L.; Kok, C.; Saunders, V.; Goyne, J.; Dang, P.; Leclercq, T.; Hughes, T.; White, D.

Discover